PT1133283E - Um metodo de producao de particulas de farmaco - Google Patents

Um metodo de producao de particulas de farmaco

Info

Publication number
PT1133283E
PT1133283E PT99963729T PT99963729T PT1133283E PT 1133283 E PT1133283 E PT 1133283E PT 99963729 T PT99963729 T PT 99963729T PT 99963729 T PT99963729 T PT 99963729T PT 1133283 E PT1133283 E PT 1133283E
Authority
PT
Portugal
Prior art keywords
particles
pharmaco
production
susceptible
degradation
Prior art date
Application number
PT99963729T
Other languages
English (en)
Inventor
Boissier Catherine
Juppo Anne Mari
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PT1133283E publication Critical patent/PT1133283E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/04—Solvent extraction of solutions which are liquid
    • B01D11/0403—Solvent extraction of solutions which are liquid with a supercritical fluid
    • B01D11/0411—Solvent extraction of solutions which are liquid with a supercritical fluid the supercritical fluid acting as solvent for the solvent and as anti-solvent for the solute, e.g. formation of particles from solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT99963729T 1998-11-23 1999-11-22 Um metodo de producao de particulas de farmaco PT1133283E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9804003A SE9804003D0 (sv) 1998-11-23 1998-11-23 A method of producing drug particles

Publications (1)

Publication Number Publication Date
PT1133283E true PT1133283E (pt) 2005-01-31

Family

ID=20413380

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99963729T PT1133283E (pt) 1998-11-23 1999-11-22 Um metodo de producao de particulas de farmaco

Country Status (12)

Country Link
US (1) US6596315B1 (pt)
EP (1) EP1133283B1 (pt)
JP (1) JP4612191B2 (pt)
AT (1) ATE278390T1 (pt)
AU (1) AU754385B2 (pt)
CA (1) CA2349711C (pt)
DE (1) DE69920945T2 (pt)
DK (1) DK1133283T3 (pt)
ES (1) ES2228148T3 (pt)
PT (1) PT1133283E (pt)
SE (1) SE9804003D0 (pt)
WO (1) WO2000030612A1 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
CA2290893C (en) * 1999-11-16 2007-05-01 Bernard Charles Sherman Magnesium omeprazole
GB0016040D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
AU2002221320B2 (en) * 2000-12-08 2006-06-15 The University Of Sydney Synthesis of small particles
AUPR197000A0 (en) * 2000-12-08 2001-01-11 Unisearch Limited Synthesis of small particles
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
EP1478386A4 (en) 2002-02-25 2005-12-28 Phasex Corp METHOD OF DRYING WATER-BASED MATERIALS
WO2003088951A1 (en) * 2002-04-15 2003-10-30 Eiffel Technologies Limited Formulation of fine particles using liquefied or dense gases
US7612098B2 (en) 2002-08-30 2009-11-03 Dr. Reddy's Laboratories Limited Amorphous hydrous esomeprazole magnesium
WO2004046134A2 (en) * 2002-11-18 2004-06-03 Dr. Reddy's Laboratories Limited Crystalline form ii of esomeprazole magnesium trihydrate and process for its preparation
EP1624862B1 (en) 2003-05-08 2014-12-31 Nektar Therapeutics Particulate materials
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2007009164A1 (en) 2005-07-15 2007-01-25 Eiffel Technologies Limited Method of particle formation
WO2007138606A2 (en) * 2006-06-01 2007-12-06 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
CA2677838C (en) 2007-02-11 2017-08-01 Map Pharmaceuticals, Inc. Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
MX350838B (es) 2011-02-11 2017-09-18 Grain Proc Corporation * Composicion de sal.
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3744329A1 (de) 1987-12-28 1989-07-06 Schwarz Pharma Gmbh Verfahren zur herstellung einer mindestens einen wirkstoff und einen traeger umfassenden zubereitung
KR0132576B1 (ko) * 1988-10-05 1998-04-17 로렌스 티. 웰츠 항-용매 내로의 침전을 통한 미분 고형물 결정 분말의 제조 방법
WO1994008599A1 (en) * 1992-10-14 1994-04-28 The Regents Of The University Of Colorado Ion-pairing of drugs for improved efficacy and delivery
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
ATE236617T1 (de) * 1994-12-22 2003-04-15 Astrazeneca Ab Aerosol-arzneiformulierungen
CA2234957C (en) * 1995-10-17 2006-12-19 Inge B. Henriksen Insoluble drug delivery
SE510666C2 (sv) * 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer

Also Published As

Publication number Publication date
ATE278390T1 (de) 2004-10-15
CA2349711C (en) 2008-07-15
US6596315B1 (en) 2003-07-22
WO2000030612A1 (en) 2000-06-02
DE69920945D1 (de) 2004-11-11
JP4612191B2 (ja) 2011-01-12
ES2228148T3 (es) 2005-04-01
AU754385B2 (en) 2002-11-14
DE69920945T2 (de) 2005-08-25
EP1133283A1 (en) 2001-09-19
SE9804003D0 (sv) 1998-11-23
DK1133283T3 (da) 2005-01-24
EP1133283B1 (en) 2004-10-06
JP2002530317A (ja) 2002-09-17
CA2349711A1 (en) 2000-06-02
AU2010200A (en) 2000-06-13

Similar Documents

Publication Publication Date Title
PT1133283E (pt) Um metodo de producao de particulas de farmaco
MXPA03010201A (es) Derivados de 2-piridin-ciclohexan-1,4-diamina sustituidos.
MXPA06007171A (es) Derivados de ciclohexano espirociclicos con afinidad para el receptor orl1.
WO2001034835A3 (en) Method for the production of biopolymers with modified properties
IS5884A (is) Aðferð til framleiðslu á hreinu sítalóprami
DK0859766T3 (da) Chirale methylphenyloxazolidinoner
PL364598A1 (en) Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
WO2001010816A3 (de) Substituierte 2-Dialkylaminoalkylbiphenyl-derivate
TR199800608A3 (tr) Propanolamin türevleri, bunlarin üretim usulü.
ES2160410T3 (es) Preparados de complejos de protrombina inmunotolerantes.
IS7239A (is) Aðferð til framleiðslu á essítalóprami
WO2002030870A3 (de) Substituierte c-cyclohexylmethylamin-derivate
ES2191449T3 (es) Derivados de ciclopentabenzofurano y su uso.
EA200300727A1 (ru) Производные 2h-1-бензопирана, способы их получения и их фармацевтические композиции
BRPI0408117A (pt) compostos heterocìclicos bifuncionais e métodos de produção e uso dos mesmos
BR0114380A (pt) Derivados-1-aminobutan-3-ol-substituìdos
IT1317722B1 (it) Procedimento per la produzione di gas di sintesi.
BR9916460A (pt) Produção de ácido ascórbico usando levedura
TR200000441A3 (tr) Organik azitlerin imali için islem.
ITRM20010309A1 (it) Procedimento per la produzione di composti perfluoro-organici mediante florurazione elettrochimica.
NO20020308D0 (no) Fremgangsmåte for fremstilling av epothiolon B og derivater, såvel som mellomprodukter for fremgangsmåten
MXPA04004526A (es) N-metil-homocisteinas, su uso y metodo para su produccion.
HK1049026A1 (zh) L-薄荷醇的製備方法
IS5020A (is) Aðferð til framleiðslu á fenoxýfenýlsúlfónýl halíðum
MXPA02003639A (es) Proceso nuevo para la sintesis de (3as)-5, 5-dioxo-2, 3, 3a-4- tetrahidro-1h-pirrolo[2, 1c][1, 2, 4] benzotiadiazina.